TomoTherapy Issues Treatment Quality Challenge
MADISON, Wis – March 25, 2008 – TomoTherapy Incorporated (NASDAQ: TOMO), maker of the Hi·Art® treatment system for advanced radiation therapy, announced today that it has issued a Treatment Quality Challenge. TomoTherapy will award $250,000 to any U.S. cancer center that demonstrates its ability to beat the quality of a TomoTherapySM treatment plan using the new RapidArc™ product from Varian Medical Systems.
“We believe that, even as radiation therapy vendors work to improve clinical efficiency, the highest-quality patient treatments must remain our industry’s primary focus,” said Fred Robertson, CEO of TomoTherapy. “With this challenge, we aim to provide a forum for U.S. clinicians and physicists to objectively review the quality that a continuous helical TomoTherapy treatment affords over a two-minute, single-rotation RapidArc™ delivery.”
Cancer centers are encouraged to learn more about this challenge and to register here.
About TomoTherapy Incorporated
TomoTherapy Incorporated has developed, markets and sells the TomoTherapy® Hi·Art® treatment system, an advanced radiation therapy system for the treatment of a wide variety of cancers. The Hi·Art treatment system combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. The company’s stock is traded on the NASDAQ Global Select Market under the symbol TOMO.
26 Mar 2008
